The diagnostic is designed to help visualise prostate cancer, offering information on the status of the disease and allowing personalised treatment.
Under the agreement, Theragnostics will be responsible for the development of GalliProst, while GE Healthcare will lead pre and post-approval commercial activities along with distribution activities.
The diagnostic process for prostate cancer typically involves a blood or biopsy test, followed by PET / CT imaging to visualise tumour, lymph nodes and any metastasis to help decide the treatment plan.
GalliProst provides a ‘heatmap’ style image, which displays the exact location and intensity of PSMA expressed on the surface of prostate cancer cells, said GE Healthcare.
GE Healthcare pharmaceutical diagnostics business Molecular Imaging Oncology global product leader Sanka Thiru said: “We believe that this partnership enables both parties to leverage each other’s key areas of expertise in order to accelerate the development of GalliProst and ultimately improve patient care.”
In Phase II clinical study, Theragnostics’ imaging agent met the primary and secondary endpoints.
Data shows GalliProst scan led to a modification in treatment plans of around 33% of newly diagnosed patients and more than 50% of those with biochemically recurrent prostate cancer.
The company noted a 75% increase in patient management during post-radical radiotherapy setting.
Theragnostics CEO Greg Mullen said: “This agreement is the validation of the potential for our novel prostate cancer Gallium-68 (68Ga) diagnostic tracer, GalliProst which can benefit the treatment of prostate cancer patients around the globe.
“We are very pleased to sign our second agreement with GE Healthcare following our agreement last year for a diagnostic tracer for imaging kidney function and scarring.”